Inapill的动态

After a few turbulent years, the biotech industry is finding its footing in 2024! Venture investment has stabilized, with U.S. private drug companies raising $3.8 billion in Q1, matching last year's pace. New venture groups like Regeneron's arm and Goldman Sachs' life sciences fund are emerging, while established players like Arch Venture Partners and Canaan Partners are gearing up for big investments. Despite a dip in preclinical funding, clinical-stage biotechs are thriving, attracting more selective and strategic investments. The future looks bright for biotech!

This weeks funding from the Diagnostics industry has a few stand out deals including.. ??GenEdit raised $24M of Series B venture funding lead by DSC Investment's. The company has not stated exactly what these funds will be for, however, Sequoia Capital, Korea Investment Partners, DAYLI Partners to name a few also participated in the round - Kunwoo Lee ??Augere Medical AS raised ￡1.62M of venture funding from undisclosed investors, however, these funds will be used to strengthen the European Sales & Marketing Efforts - Pia Helén Smedsrud ??Rhythm Biosciences Limited is in talks to receive ￡1.79M of development capital from undisclosed investors. The proceeds from this will be used to fund ColoSTAT Multiplex test kit development - ??Theranautilus raised $1.2M of seed funding in a deal lead by pi Ventures. The funds will be used to set up an ISO-Certified manufacturing facility, advance its clinical developments and prepared for human trials planned for 2025 - Debayan Dasgupta ~~~ ?? Enjoy this post? ?? hey there, i’m nathan - i partner with companies across the life science and biotech space to build great teams - if you want more cool insights like this, follow me or sign up for our weekly newsletter

?? After a few turbulent years, the biotech industry is finding its footing in 2024! ?? Venture investment has stabilized, with U.S. private drug companies raising $3.8 billion in Q1, matching last year's pace. New venture groups like Regeneron's arm and Goldman Sachs' life sciences fund are emerging, while established players like Arch Venture Partners and Canaan Partners are gearing up for big investments. Despite a dip in preclinical funding, clinical-stage biotechs are thriving, attracting more selective and strategic investments. The future looks bright for biotech! ?? #Biotech #VentureCapital #Innovation #Investment #Biotechnology

Biotech Investor Preferences Shift - Companies Need to Walk Through Their Journey to Commercial Success Private biotech companies, even those in earlier stages, must have a compelling commercialization story to attract investor interest. Investors prefer backing companies with strong scientific foundations and robust clinical pipelines. They also increasingly expect companies to articulate a clear story about the unmet need in their target disease and the role their medicine will play. Describing the path to commercialization is crucial. This can be a challenging exercise, but companies are failing because they are not able to do this effectively. Fundraising Best Practices (abbreviated checklist) - Planning and Strategy: ??Develop Multiple Plans: Always have a Plan B and Plan C ready, especially for clinical pathways. ??Credible Commercialization Pathway: Ensure a clear and credible commercialization pathway. ??Clear Storytelling: Companies often fail due to unclear communication of the unmet need and the role of their medicine. Simplify for investors but add nuance for disease experts. Communication and Storytelling: ??Tailor Communication: Differentiate your messaging for investors (simple, clear) versus disease experts (nuanced, detailed). ??Dual Presentations: Have two versions of your presentation – one scientific and one financial. ??Highlight Commercial Opportunity Early: Emphasize the commercial potential early in the process, not just the science. ??Evolve Your Story: Continuously update and adapt your story as your project and the external environment evolve. Team and Capabilities: ??Highlight Capabilities: Clearly articulate why your team is the right one and what unique skills they bring. ??Focus on Unfair Advantage: Identify and communicate your company's unique advantages and strengths. ??Capabilities Across Functions: Highlight capabilities in critical areas like CMC (Chemistry, Manufacturing, and Controls), supply chain management, and other operational aspects. Commercial and Market Considerations: ??Early Market Planning: Integrate commercial thinking from the preclinical stage. ??Scenario Planning: Conduct scenario planning to understand how your product will compete in the market. ??Understand the Market: Research the current therapeutic market, treatment guidelines, reimbursement decisions, and competition. Safety and Manufacturing: ??Focus on Safety and Manufacturing: Address safety concerns and manufacturing capabilities as top priorities. Long-term Vision and Adaptability: ??Adapt to Changes: Be ready to adapt your story and strategy as external circumstances and market trends change. ? #privatebiotechfundraising #fundraising #biotech https://lnkd.in/eg8a9XWW

?? After a few turbulent years, the biotech industry is finding its footing in 2024! ?? Venture investment has stabilized, with U.S. private drug companies raising $3.8 billion in Q1, matching last year's pace. New venture groups like Regeneron's arm and Goldman Sachs' life sciences fund are emerging, while established players like Arch Venture Partners and Canaan Partners are gearing up for big investments. Despite a dip in preclinical funding, clinical-stage biotechs are thriving, attracting more selective and strategic investments. The future looks bright for biotech! ?? #Biotech #VentureCapital #Innovation #Investment #Biotechnology

We’re so excited to announce the Biotech Ecosystem Fund—a new fund in partnership with Eli Lilly and Company.? With a mission to fuel innovation, this fund aims to: ? Invest in therapeutic platforms and cutting-edge technologies at all stages—from creation to growth. ? Support biotech startups in scaling novel medicines and emerging health technologies. ? Take a long-term approach to unlock the full potential of biological science, engineering technologies, and AI capabilities. By combining a16z's expertise in building bio + health companies with Lilly’s life science R&D expertise and resources like Catalyze360?, this partnership is distinctly positioned to empower founders and accelerate progress towards new modalities, new medicines and importantly, improved patient outcomes. Together, we’re building a future where transformative therapies reach patients faster. None of the above should be taken as investment advice or an advertisement for investment services; please see https://lnkd.in/gjmYWkHi for more information.?

Propelling Future Lifelines ? A humble giant driving innovative therapies and technologies through strategic corporate investment in early-stage biotech startups brought its core business teams to HK – a big thanks to?150+?guests?who joined us at Boehringer Ingelheim?x Incu-Bio Open Day! ? Leveraging our strategic co-incubation partnership with Boehringer Ingelheim Venture Fund (BIVF), the open day was a great opportunity for the local biomed community to learn about the breadth of?world-leading pharma?Boehringer Ingelheim’s expertise from venture funding to business development, licensing, and contract development and manufacturing organisation?(CDMO). ? During fireside chats, BIVF, The Chinese University of Hong Kong, Boehringer Ingelheim leaders, and a BIVF portfolio company?shared insightful experiences of venture building, and how they support startups during the translational journey to address industry pain points. Seven?Park companies pitched their?projects?to an investors’ panel with constructive feedback. It?underscores just how strategic partnerships can take biomed innovations to great lengths! ? We partner with world-leading?biomedical?companies to co-incubate startups in life?and health tech. Interested??stp.hk/4iHcclM ? #HKSTP #PropellingSuccess #BioTech

?? Atlas Venture Raises $450M to Power the Next Wave of Biotech Innovation! ???? Massachusetts-based Atlas Venture has announced its fourteenth fund with an impressive $450M, mirroring the size of its previous fund in 2022. Over the past two years, Atlas has launched 16 new biotech companies, partnered with 100+ executive leaders, and celebrated major wins, including: ?? Eli Lilly and Company's acquisition of Versanis Bio ?? GSK's $1B buyout of Aiolos Bio ?? Novartis' $1B deal for Mariana Oncology ?? Notable IPOs: Disc Medicine, Korro Bio, Inc. , Q32 Bio Inc. , and Third Harmonic Bio have taken the leap to go public, showcasing the firm’s robust portfolio and venture creation strategy. Atlas emphasises its “disciplined, focused approach”, building biotechs across disease areas, modalities, and business models while maintaining strong partnerships with supportive limited partners (LPs). ?? The latest addition to its portfolio? Trace Neuroscience, with $101M in Series A funding, aiming to revolutionise genomic medicine for ALS. In a biotech market buzzing with activity, Atlas joins other major players like Bain Capital and ARCH Venture Partners, who recently launched multi-billion-dollar healthcare funds. ?? #BiotechFunding #VentureCapital #Innovation #LifeSciences #AtlasVenture #HealthcareInvesting

The US has been experiencing a decline in life expectancy since 2014. But the past year has been the first time in a long time that I've been excited about the potential of health related startups to start making a real impact. Actually improving health outcomes vs just prescribing more medicine has been an uphill battle for the past decade or more. Recently though, it feels like there is finally starting to be a shift in public perception that the answer isn't just more medicine to treat conditions, but a more functional approach to eliminate chronic disease. Very exciting to see a16z Bio + Health lean into health investing more deeply with this new $500M fund. Even though the fund is primarily focused on new therapeutics, the mention of "cutting-edge technologies," "emerging health," and taking a "long-term approach," are all small signals to me (paired with their other investments recently into more functional health companies and approaches), that we are in the early phases of a health renaissance. Maybe it's wishful thinking. Let's hope not.

Amidst challenges, venture investment in biopharma and medtech companies trend up. Learn more from our industry executives Kathryn McDonough and Skip Kelly in our Q1 reports, powered by DealForma.